Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Chinese Patients With Active Moderate-Severe Systemic Lupus Erythematosus (LOTUS)
NCT07751848Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Primary endpoint: Definition of Remission in SLE (DORIS) remission at 52 weeks. Started Aug 2026; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07751848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751848.